Search

Your search keyword '"Rossignol R"' showing total 277 results

Search Constraints

Start Over You searched for: Author "Rossignol R" Remove constraint Author: "Rossignol R"
277 results on '"Rossignol R"'

Search Results

101. β2-adrenergic signals downregulate the innate immune response and reduce host resistance to viral infection.

102. Doxorubicin Inhibits Phosphatidylserine Decarboxylase and Modifies Mitochondrial Membrane Composition in HeLa Cells.

103. Metabolic reprogramming by tobacco-specific nitrosamines (TSNAs) in cancer.

104. Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F.

105. UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis.

106. Bioenergetic Changes Underline Plasticity of Murine Embryonic Stem Cells.

107. PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers.

108. Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells.

109. Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation.

110. Early Retinal Defects in Fmr1 -/y Mice: Toward a Critical Role of Visual Dys-Sensitivity in the Fragile X Syndrome Phenotype?

111. Mitochondria in cancer.

112. Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor κB and its ligand signalling in rheumatoid arthritis.

113. Mitochondrial morphology and cellular distribution are altered in SPG31 patients and are linked to DRP1 hyperphosphorylation.

114. Signaling Pathways Linked to Serotonin-Induced Superoxide Anion Production: A Physiological Role for Mitochondria in Pulmonary Arteries.

115. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.

116. Enhanced OXPHOS, glutaminolysis and β-oxidation constitute the metastatic phenotype of melanoma cells.

117. New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay.

118. The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism.

119. Redox Homeostasis and Mitochondrial Dynamics.

120. Energy metabolism disorders in rare and common diseases. Toward bioenergetic modulation therapy and the training of a new generation of European scientists.

121. Premature skin aging features rescued by inhibition of NADPH oxidase activity in XPC-deficient mice.

122. Identifying the most sensitive and specific sign and symptom combinations for cholera: results from an analysis of laboratory-based surveillance data from Haiti, 2012-2013.

123. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy.

124. Hypoxia/hypercapnia-induced adaptation maintains functional capacity of cord blood stem and progenitor cells at 4°C.

125. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease.

126. Pathological similarities between low birth weight-related nephropathy and nephropathy associated with mitochondrial cytopathy.

127. Visual sensorial impairments in neurodevelopmental disorders: evidence for a retinal phenotype in Fragile X Syndrome.

129. Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor.

130. Management program decreases postoperative nausea and vomiting in high-risk and in general surgical patients: a quality improvement cycle.

131. Upregulation of TFAM and mitochondria copy number in human lymphoblastoid cells.

132. Evolution of the complex permittivity of biological tissue at microwaves ranges: correlation study with burn depth.

133. The STRONG(kids) nutritional screening tool in hospitalized children: a validation study.

134. Human F1F0 ATP synthase, mitochondrial ultrastructure and OXPHOS impairment: a (super-)complex matter?

135. Podocyte energy metabolism and glomerular diseases.

136. Adaptative capacity of mitochondrial biogenesis and of mitochondrial dynamics in response to pathogenic respiratory chain dysfunction.

137. Rheb regulates mitophagy induced by mitochondrial energetic status.

138. Disruption of the histidine triad nucleotide-binding hint2 gene in mice affects glycemic control and mitochondrial function.

139. Mitoplasticity: adaptation biology of the mitochondrion to the cellular redox state in physiology and carcinogenesis.

140. Rationale for mitochondria-targeting strategies in cancer bioenergetic therapies.

141. Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia.

142. Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats.

143. Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes.

144. Local anesthetic 'in-situ' toxicity during peripheral nerve blocks: update on mechanisms and prevention.

145. Metabolic consequences of NDUFS4 gene deletion in immortalized mouse embryonic fibroblasts.

146. Acute and chronic effects of bupivacaine on muscle energetics during contraction in vivo: a modular metabolic control analysis.

147. Mitochondrial CB₁ receptors regulate neuronal energy metabolism.

148. Antiproliferative activity of levobupivacaine and aminoimidazole carboxamide ribonucleotide on human cancer cells of variable bioenergetic profile.

149. REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction.

150. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells.

Catalog

Books, media, physical & digital resources